Partner Jeffrey Fessler Represents Synergy Pharmaceuticals Inc. on $89.8 Million Registered Direct Offering of Common Stock
Press Release – New York, NY – May 6, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, on a registered direct offering of 29,948,334 shares of the Company’s common stock at a public offering price per share of $3.00 without an underwriter or placement agent.
Synergy raised $89.8 million in gross proceeds.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Stephen A. Cohen.
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020
- Coronavirus (Covid 19) Update - March 16, 2020
- Founding Partner Gregory Sichenzia Featured in Law360 Article on Coronavirus-fueled Market Volatility - March 10, 2020